Patent Exceptions in the Time of a Pandemic

les Nouvelles - Journal of the Licensing Executives Society, Volume LV No. 3, September 2020

2 Pages Posted: 1 Sep 2020

See all articles by Jean Akl

Jean Akl

Saba & Co. Intellectual Property

Date Written: Sept 2020

Abstract

The blistering race and competition to find a COVID-19 vaccine is ongoing at a very fast pace. Pharmaceutical companies are scurrying to secure a legal monopoly for the treatment, to control the largest market share, and to ensure a considerable return on their investment, since the demand thereon would be immediate, global, and possibly extending for years and decades to come.

Whether it is Gilead’s Remdesivir or any other treatment or vaccine that is ultimately found to have a proven curative or preventive outcome, researchers are ramping up their efforts, all while anticipating that a second wave of coronavirus is expected to swipe the globe again, as the Spanish flu did a century ago.

Keywords: patent exceptions, pandemic, COCID-19, vaccine, pharmaceutical, Gilead’s Remdesivir

Suggested Citation

Akl, Jean, Patent Exceptions in the Time of a Pandemic (Sept 2020). les Nouvelles - Journal of the Licensing Executives Society, Volume LV No. 3, September 2020, Available at SSRN: https://ssrn.com/abstract=3658629

Jean Akl (Contact Author)

Saba & Co. Intellectual Property ( email )

Doha
Qatar

Here is the Coronavirus
related research on SSRN

Paper statistics

Downloads
41
Abstract Views
591
PlumX Metrics